Novartis announced positive Phase 3 results for its B cell-targeting antibody ianalumab in Sjögren’s syndrome and primary immune thrombocytopenia (ITP). Both large registrational trials demonstrated statistically significant improvements in disease activity and favorable safety profiles. These wins position ianalumab as a leading targeted treatment option for these challenging autoimmune disorders. Novartis is planning regulatory submissions based on the data.